Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma

Authors
Amato, David A.
Bruckner, Howard
Guerry, DuPont IV
Ash, Arlene S.
Falkson, Geoffrey
Borden, Ernest C.
Creech, Richard H.
Savlov, Edwin D.
Cunningham, Thomas J.
UMass Chan Affiliations
Department of Quantitative Health Sciences
Document Type
Journal Article
Publication Date
1987-01-01
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
effects
Cyclophosphamide
Dactinomycin
Drug Evaluation
Female

Metadata
Show full item record
Link to Full Text
http://dx.doi.org/10.1007/BF00175301
Abstract
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.
Source
Invest New Drugs. 1987;5(3):293-7. Link to article on publisher's site
DOI
10.1007/BF00175301
Permanent Link to this Item
http://hdl.handle.net/20.500.14038/47484
PubMed ID
3667165
Related Resources
Link to Article in PubMed
Collections